Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791195 | 0.86 | DRD2 (0.61) | DRD2DRD3DRD4GAAMAPT | |
| SCHEMBL29046800 | 0.84 | DRD2 (0.66) | DRD2DRD3DRD4GAAMAPT | |
| SCHEMBL23102103 | 0.84 | DRD2 (0.68) | DRD2DRD3DRD4GAAMAPT | |
| SCHEMBL7699834 | 0.83 | DRD2 (0.47) | DRD2DRD3DRD4GAAKDM4E | |
| SCHEMBL11786956 | 0.82 | LMNA (0.57) | DRD2DRD3GAAKDM4ELMNA | |
| SCHEMBL7732059 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4GAAMAPT | |
| SCHEMBL5113532 | 0.81 | DRD2 (0.65) | DRD2DRD3DRD4GAAMAPT | |
| SCHEMBL7534110 | 0.81 | DRD2 (0.65) | DRD2DRD3DRD4GAAMAPT | |
| SCHEMBL2161623 | 0.81 | DRD2 (0.58) | DRD2DRD3DRD4GAAMAPT | |
| SCHEMBL7094582 | 0.80 | GAA (0.55) | DRD2DRD3DRD4GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | DRD2 2649/4885DRD3 3283/4885DRD4 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.